CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component

What's the purpose of the trial?

The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
Trial status

Accepting patients

Phase
Phase 1
Enrollment
111
Last Updated
3 days ago
Am I Eligible

Participating Centers

There are 17 centers participating in this trial. Enter a location below to find the closet center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Alnuctamab
  • BMS-986393 (CC-95266)
  • Iberdomide
  • Mezigdomide

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Part 1: BMS-986393 + Alnuctamab

Accepting patients

Part 1: BMS-986393 + Mezigdomide

Accepting patients

Part 1: BMS-986393 + Iberdomide

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 354-2873

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.